Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Tria

Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients



Company Remains On-Track to Report Top Line Data by End of 2Q 2024

Related Keywords

South Korea , Australia , United States , Japan , United Kingdom , America , Pharma Gmb , Matt Pauls , Savara Inc , Drug Administration , Linkedin , Twitter , Nasdaq , Healthcare Products Regulatory Agency , Breakthrough Therapy Designation , New England Journal , Promising Innovative Medicine , Innovative Passport Designation , North America , Respiratory Questionnaire , Total Score , Component Score , Nebulizer System , Private Securities Litigation Reform Act ,